Announcement of 2020 annual general meeting passes removal of the noncompete clause for directors

OBI filled application of Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858, to TFDA
June 10, 2020
Announcement of resolution items from 2020 Annual General Meeting
June 22, 2020
  1. Date of the shareholders’ meeting resolution: Jun 22, 2020
  2. Name and title of the managerial officer with permission to engage in competitive conduct:

Director: Frank Chen (Sheng Cheng Investment Co., Ltd. representative)

  1. Items of competitive conduct in which the officer is permitted to engage: business items that are in the scope of business similar to company’s operation
  2. Period of permission to engage in the competitive conduct: for the duration of serving as a director of the company
  3. Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act): proposal has been passed as is by a majority vote of the shareholders present in a meeting attended by shareholders representing half of the shares outstanding.
  4. If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors

(if it is not the operator of a mainland China enterprise, please enter “N/A” below): N/A

  1. Company name of the mainland China enterprise and the officer’s position in the enterprise: N/A
  2. Address of the mainland China enterprise: N/A
  3. Operations of the mainland China enterprise: N/A
  4. Impact on the company’s finance and business: N/A
  5. If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio: N/A
  6. Any other matters that need to be specified: None